Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Page 10 of 15
Apr 24, 2026Treehub represents a targeted effort to nurture innovation in healthcare AI by providing critical early-stage support and resources. Prominent investors like Tim Draper and Anne Wojcicki are among those spearheading this initiative, signaling strong confidence in the potential of AI-driven solutions in healthcare.
Apr 21, 2026In the first quarter of 2026, UnitedHealth exceeded analyst forecasts in both its Optum and UnitedHealthcare businesses. However, the company continues to face ongoing hurdles in the evolving healthcare landscape, reflecting complex market dynamics.
Apr 20, 2026With analysts expressing cautious optimism about an IPO rebound in biopharma this year, industry watchers are tracking a variety of companies preparing to enter the public markets. This article explores key trends, challenges, and the potential impact of renewed investor interest on the biopharmaceutical landscape.
Apr 20, 2026In a strategic move set to bolster the development of tumor-infiltrating lymphocyte (TIL) therapies, Obsidian Therapeutics and Galera Therapeutics have merged, securing substantial financial backing. This merger is poised to accelerate clinical trials and development pipelines designed to improve cancer treatment options for melanoma patients worldwide.
Apr 17, 2026In a milestone event for biotech investments, Kailera Therapeutics surpassed the previous IPO fundraising record held by Moderna from 2018. This groundbreaking success highlights the competitive landscape of obesity drug development and underscores the growing investor interest in therapeutics targeting metabolic diseases. This article delves into Kailera's record-breaking IPO, the strategic positioning of the company within the obesity treatment market, and what this means for future biotech funding.
Apr 13, 2026The Centers for Medicare & Medicaid Services (CMS) recently greenlit a broad set of digital health companies to take part in its ACCESS experiment, a new pilot program designed to transform chronic care through technology-enabled solutions and outcome-aligned payment models. This initiative represents a significant step toward integrating innovative technologies into Medicare’s chronic care management.
Apr 7, 2026The digital health sector experienced a surge in capital inflows during Q1 2026, driven predominantly by megadeals. This reflects a strategic shift in investor behavior towards concentrated bets on select startups with potential for significant impact in healthcare innovation.
Apr 4, 2026The health technology arena continues to attract substantial capital, with key players securing investments to advance digital health solutions, medical devices, and AI-driven platforms. This overview highlights four notable funding announcements that underscore ongoing trends and potential industry shifts.
Apr 3, 2026In a strategic move to facilitate better nutritional health, Amazon has teamed up with Berry Street to offer insurance-covered nutrition therapy services through its platform, aiming to increase accessibility and awareness among users. This development reflects the growing significance of nutrition therapy in healthcare.
Mar 29, 2026The assessment of return on investment (ROI) for AI initiatives within health systems is undergoing a significant transformation. As budgetary pressures intensify, leaders are adopting expanded frameworks that value not only direct cost savings but also indirect benefits like improved clinician well-being and operational efficiencies, marking a paradigm shift in how these technologies are integrated.
Mar 24, 2026Rachel Springate of Muse Capital explains why pure DTC approaches rarely succeed in healthcare. Companies that start with patient needs and integrate clinical data and payers show a promising new path for healthcare startups.
Mar 22, 2026The infusion of new capital into Lantern highlights ongoing interest and confidence in innovative healthcare solutions tailored to employers and insurers. Such investment initiatives often aim to improve healthcare delivery and cost management through strategic technology development and partnerships.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.